Sensei is developing a pipeline of investigational medicines that have potential to alter the relationship between host immune cells and cancer so that the immune system recognizes tumors as a threat and unleashes an immune response.
The TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Our current pipeline candidates are designed to be active only within the low-pH tumor microenvironment.
*Sensei has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. The goal of this collaborative effort is to further elucidate the role of VISTA in immune checkpoint resistance and expand the potential of SNS-101 as a combination therapy beyond anti-PD-1.
*Sensei has entered into a clinical supply agreement with Regeneron supporting the planned evaluation of SNS-101 in combination with Regeneron’s anti-PD-1 therapy Libtayo®️ (cemiplimab) in a Phase 1/2 clinical trial in solid tumors.